SCHILLER, a leading international manufacturer and supplier of cardiopulmonary diagnostics, and BSP Biological Signal Processing, a medical device company that develops and markets innovative solutions for non-invasive diagnosis and monitoring of ischemic heart disease, have successfully integrated BSP's HyperQ™ analyzer in SCHILLER's ECG diagnostic system, the CS-200 Excellence. The integrated system was launched and exhibited at the MEDICA 2009 international trade fair in Düsseldorf, Germany.
The CS-200 Excellence provides the highest diagnostic accuracy and sets new standards for the future in electrocardiology. Its extremely high amplitude resolution of 24bits and sampling frequency of 8,000Hz enable extremely accurate detection of ST alterations. The integrated rechargeable battery and printer make the unit the world's first autonomous emergency ECG system. With the familiar SCHILLER interface and intuitive operation via direct keys, the 12/16-channel electrocardiograph provides optimum prerequisites for the highest productivity and efficiency.
The HyperQ analyzer is based on a groundbreaking technology for non-invasive diagnosis of ischemic heart disease. Utilizing advanced signal processing, HyperQ extracts and analyzes valuable clinical information from high-resolution ECG signals, providing a novel diagnostic tool with superior accuracy, compared with conventional stress ECG analysis. To date, over 15,000 patients have been tested using the HyperQ analysis, in routine use and in clinical studies, with exceptionally promising results.
SCHILLER plans to install 25 evaluation units of the HyperQ-enabled CS-200 Excellence in leading cardiology centres in Europe and the US. The evaluation will be followed by worldwide marketing and sales of the integrated system.
Dr Amir Beker, founder and CEO of BSP, says: "Launching the HyperQ-enabled CS-200 Excellence system marks a significant milestone in the process of implementation and adoption of HyperQ analyzer as an essential clinical tool for the practicing cardiologist. We are proud to partner with SCHILLER in leading a remarkable step forward in the non-invasive diagnosis and management of ischemic heart disease."
